Day: March 7, 2024

On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong financial position with $463.8 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update. “2023 was a watershed year for Neumora as we transitioned to a publicly traded company, advanced our KOR antagonist, navacaprant, into three Phase 3 registrational studies, and brought our M4 PAM, NMRA-266,...

Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024 On track to initiate Phase 2 study of Descartes-08 in systemic lupus erythematosus (SLE) in 1H24 as well as Phase 2 basket studies in additional autoimmune indications in 2H24 Following recent IND clearance, planning underway for first-in-human Phase 1 dose escalation study of Descartes-15, a next-generation mRNA CAR-T product candidate Approximately $118.3M pro forma cash, cash equivalents, and restricted cash as of December 31, 2023, expected to support planned operations into second half of 2026 GAITHERSBURG, Md., March 07, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering...

–  Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024  – –  WTX-124 recommended dose for expansion (RDE), initiation of monotherapy dose expansion arms and initial combination dose-escalation data also expected in the first half of 2024  – –  Preliminary data from Phase 1 clinical trial of WTX-330 expected in the second quarter of 2024  – –  Updated cash guidance provides runway through at least the second quarter of 2025  – WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today...

Record Fourth Quarter Net Revenue of $135.8 million, up 23.4% versus Prior Year PeriodProvides Fiscal Year 2024 Outlook AUSTIN, Texas, March 07, 2024 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today reported financial results for its fourth quarter (14 weeks) and fiscal year (53 weeks) ended December 31, 2023. Financial highlights for the fourth quarter ended December 31, 2023 (14 weeks) compared to the fourth quarter ended December 25, 2022 (13 weeks):Net Revenue increased 23.4% to $135.8 million, compared to $110.1 million. Excluding the extra week in the fourth quarter, Net Revenue increased 15.7%. Net Income of $7.2 million, compared to $1.9 million. Net Income per Diluted Share of $0.17, compared to $0.04. Adjusted EBITDA of $13.9 million,...

– Earned 1,236 BTC in Q4 2023 and 4,928 BTC in 2023 –– Improved Q4 2023 gross mining margin to 52%, up from 38% in Q3 2023 –– Achieved debt-free goal in February 2024, enhancing financial flexibility –– Executing towards targets of 12 EH/s and 25 w/TH by end of Q2 2024 and 21 EH/s by end of 2024 – TORONTO, Ontario and BROSSARD, Québec, March 07, 2024 (GLOBE NEWSWIRE) — Bitfarms Ltd. (Nasdaq/TSX: BITF), a global Bitcoin vertically integrated company, reported its financial results for the fourth quarter and year ended December 31, 2023. All financial references are in U.S. dollars. “In 2023, we set the foundation to drive significant growth through our transformational fleet upgrade and mining facility expansion,” said Geoff Morphy, President and Chief Executive Officer of Bitfarms....

Development of tariffs for licensed servicesDevelopment of tariffs for licensed services 2014-2024Reykjavík Energy (RE; Orkuveita Reykjavíkur) financial position according to the 2023 financial statements is a promising start for the transformation projects that the company and Icelandic society are facing. This is according to Sævar Freyr Þráinsson, CEO, who is implementing the company‘s new overall strategy and introducing a new organisational structure. Profit but High Financial CostsReykjavík Energy operated with a profit of ISK 6.4 billion in 2023, and the year’s investments amounted to ISK 29.2 billion. The consolidated annual financial statements of RE were approved by the Board of Directors today. In addition to the parent company, RE includes Veitur Utilities, ON Power, Reykjavík Fibre Network, and Carbfix. Revenues...

LUXEMBOURG, March 07, 2024 (GLOBE NEWSWIRE) — Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider and marketplace for the real estate and mortgage industries, today reported financial results for the fourth quarter and full year 2023. “I am pleased with our performance in 2023 as we continue to strengthen our financial position and win new business which has not fully ramped. In the face of serious market headwinds for both Business Segments, Service revenue in the Servicer and Real Estate segment was only 4% lower than 2022 and Service revenue in the Origination segment outperformed the overall market with a decline of 11% compared to a 36% decline in industrywide residential origination volume. We improved total company Adjusted EBITDA(2) by $15.7 million compared to 2022 and...

Full Year 2023 Record Net Revenue of $1.3 BillionAnnounces Special Cash Dividend and Full Year 2024 Guidance BOSTON HEIGHTS, Ohio, March 07, 2024 (GLOBE NEWSWIRE) — Arhaus, Inc. (NASDAQ: ARHS; “Arhaus” or the “Company”), a rapidly growing lifestyle brand and omni-channel retailer of premium artisan-crafted home furnishings, reported unaudited financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 HighlightsNet revenue of $344 million Comparable growth(1) of (6.8)% Net and comprehensive income of $31 million Adjusted net income of $31 million Adjusted EBITDA of $51 millionFull Year 2023 HighlightsNet revenue of $1.3 billion Comparable growth(1) of 1.4% Net and comprehensive income of $125 million Adjusted net income of $126 million Adjusted EBITDA of $203 millionFull Year 2024...